Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery

Anticancer Research

Volumn 28, Issue 3 B, 2008, Pages 1951-1954

  Caprotti, R ^a   Brivio, F ^a   Fumagalli, L ^a   Nobili, C ^a   Degrate, L ^a   Lissoni, P ^a   Parolini, D ^a   Messina, G ^a   Colciago, M ^b   Scotti, M ^a   Uggeri, F ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b INRCA   (Italy)

Author keywords

Immunosurgery; Immunotherapy; Interleukin 2; Lymphocytopenia; Pancreatic cancer

Indexed keywords

CISPLATIN; GEMCITABINE; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 45949109152     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hansel DE, Kern SE and Hruban RH: Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet 4: 237-256,2003.
2. Siegel PM and Massague J: Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3: 807-821,2003.
3. Elliott RL and Blobe GC: Role of transforming growth factor-beta in human cancer. J Clin Oncol 23: 2078-2093, 2005.
4. Furukawa T, Sunamura M and Horii A: Molecular pathogenesis of pancreatic cancer. Cancer Sci 97: 1-7, 2006.
5. Birebent B, Lorho R, Lechartier H, de Guilbert S, Alizadeh M, Vu N, Beauplet A, Robillard N and Semana G: Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression. Eur J Immunol 34: 3485-3496, 2004.
6. Truty MJ and Urrutia R: Transforming growth factor-beta: what every pancreatic surgeon should known. Surgery 141: 1-6, 2007.
7. Chen W, Jin W, Hardegen N, Lei K, Li L, Marinos N, McGrady G and Wahl SM: Conversion of peripheral CD4+CD25- naïve T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198: 1875-1886, 2003.
8. Akiyoshi T, Koba F, Arinaga S, Miyazaki S, Wada T and Tsuji H: Impaired production of interleukin-2 after surgery. Clin Exp Immunol 59: 45-49, 1985.
9. Akiyoshi T, Koba F, Arinaga S, Wada T and Tsuji H: In vitro effect of interleukin-2 on depression of cell-mediated immune response after surgery. Jpn J Surg 15: 375-378,1985.
10. Brivio F, Lissoni P, Tisi E, Barni S, Tancini G, Rescaldani R and Nociti V: Effect of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients: Oncology 49: 215-218, 1992.
11. Brivio F, Lissoni P, Brivio O, Marsili MT, Alderi G and Lavorato F: Timing and schedule of perioperative immunotherapy with interleukin-2 in oncological surgery. J Emerg Surg Intensive Care 19: 59-62, 1996.
12. Grimm EA, Mazumder A, Zhang HZ and Rosenberg SA: Lymphokine-activated killer cell phenomenon. J Exp Med 155: 1823-1841, 1982.
13. Friess H, Kleeff J, Kork M and Buchler MW: Molecular aspects of pancreatic cancer and future perspectives. Dig Surg 16: 281-290, 1999.
14. Whittington R and Faulds D: Interleukin-2. Drugs 46: 446-483, 1993.
15. Atzpodien J and Kirchner H: Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 68: 1-11, 1990.
16. Brivio F, Lissoni P, Barni S, Tancini G, Ardizzoia A and Erba L: Effect of preoperative course of interleumin-2 on surgical and immunological variables in patients with colorectal cancer. Eur J Surg 159: 43-47, 1993.
17. Brivio F, Fumagalli L, Lissoni P, Nardone A, Nespoli L, Fattori L, Denova M, Chiarelli M and Nespoli A: Preoperative immuno-prophilaxis with interleukin-2 may improve the prognosis in radical surgery for colorectal cancer stage B, C. Anticancer Res 26: 599-604, 2006.
18. Cerea K, Romano F, Ferrari-Bravo A, Motta V, Uggeri F, Brivio F and Fumagalli L: Phase I-b study on prevention of surgery-induced immunodeficiency with preoperative administration of low-dose subcutaneous interleukin-2 in gastric cancer patients. J Surg Oncol 78: 32-37, 2001.
19. Brivio F, Lissoni P, Fumagalli L, Brivio O, Lavorato F, Rescaldani R, Conti A, Roselli MG, Maestroni G and Barni S: Preoperative neuroimmunotherapy with subcutaneous low-dose interleukin-2 and melatonin in patients with gastrointestinal tumors: its efficacy in preventing surgery-induce lymphocytopenia. Oncol Rep 2: 597-599, 1995.
20. Fumagalli L, Lissoni P, Di Felice G, Meregalli S, Valsuani G, Mengo S and Rovelli F: Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br J Cancer 80: 407-411, 1999.
21. Regelson W and Pierpaoli W: Melatonin:a rediscovered antitumor hormone? Cancer Invest 5: 379-385, 1987.
22. Maestroni GJM: The immunoneuroendocrine role of melatonin. J Pineal Res 14: 1-10, 1993.
23. Brzezinski A: Melatonin in humans. N Engl J Med 336: 186-195, 1997.